Form 4: Janus Henderson Group PLC Increases Stake in ARCA biopharma, Inc.
SEC Form 4
Janus Henderson Group PLC, through its fund, continues to increase its holdings in ARCA biopharma, Inc., with multiple purchases of common stock.
Summary
- Janus Henderson Group PLC, along with Janus Henderson Biotech Innovation Master Fund Ltd, filed a Form 4 detailing changes in beneficial ownership of ARCA biopharma, Inc. (ABIO) common stock.
- Between July 3, 2024, and July 11, 2024, the fund purchased ABIO common stock in multiple transactions.
- The purchases were made at prices ranging from $3.41 to $3.5507 per share.
- These transactions increased the fund's holdings to 1,891,312 shares of ABIO common stock.
- Janus Henderson Group PLC may be deemed a beneficial owner due to its ownership stake in Janus Henderson Investors US LLC, the investment advisor to the fund, but disclaims beneficial ownership except to the extent of its pecuniary interest.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine filing indicating increased investment, which could be seen as mildly positive, but it doesn't contain any explicit forward-looking statements or strong endorsements.
Positives
- The increased investment by Janus Henderson could be seen as a positive signal for ARCA biopharma, indicating confidence in the company's prospects.
Risks
- The document itself doesn't explicitly mention risks, but the investment is subject to the usual market risks associated with stock ownership.
- Janus Henderson disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any.
Management Comments
- Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any.
Industry Context
Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the trading activities of significant shareholders.
Stakeholder Impact
- The increased stake by Janus Henderson could potentially increase investor confidence in ARCA biopharma.
Key Dates
| Date | Description |
|---|---|
| 07/02/2024 | Date of Earliest Transaction |
| 07/03/2024 | Purchase of 166,042 shares at $3.5507 |
| 07/05/2024 | Purchase of 23,326 shares at $3.4303 and 5,000 shares at $3.41 |
| 07/08/2024 | Purchase of 29,892 shares at $3.4114 and 17,600 shares at $3.535 |
| 07/09/2024 | Purchase of 16,917 shares at $3.4339 |
| 07/10/2024 | Purchase of 33,500 shares at $3.4647 and 21,963 shares at $3.4632 |
| 07/11/2024 | Purchase of 94,537 shares at $3.4516 |
| 07/12/2024 | Date of signature for the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.